Retrophin Inc. (NASDAQ:RTRX) shot up 3.2% during trading on Friday . The company traded as high as $18.47 and last traded at $18.33, with a volume of 268,462 shares changing hands. The stock had previously closed at $17.77.

RTRX has been the topic of a number of recent research reports. Leerink Swann restated a “buy” rating and issued a $27.00 target price on shares of Retrophin in a report on Monday, June 27th. BMO Capital Markets restated a “buy” rating on shares of Retrophin in a report on Monday, June 20th. Zacks Investment Research upgraded Retrophin from a “hold” rating to a “buy” rating and set a $17.00 target price on the stock in a report on Saturday, April 16th. Finally, JMP Securities restated a “buy” rating on shares of Retrophin in a report on Saturday, July 9th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Retrophin currently has an average rating of “Buy” and a consensus price target of $23.60.

The firm has a market cap of $664.57 million and a price-to-earnings ratio of 9.43. The company has a 50 day moving average price of $17.90 and a 200 day moving average price of $15.94.

Retrophin (NASDAQ:RTRX) last released its quarterly earnings results on Tuesday, May 3rd. The biopharmaceutical company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.36. The business had revenue of $29 million for the quarter, compared to the consensus estimate of $31 million. During the same period in the previous year, the company earned ($0.18) EPS. The company’s revenue for the quarter was up 66.7% on a year-over-year basis. Equities research analysts anticipate that Retrophin Inc. will post $0.08 EPS for the current fiscal year.

In other Retrophin news, EVP Alvin Shih sold 8,750 shares of the company’s stock in a transaction that occurred on Wednesday, June 1st. The stock was sold at an average price of $17.75, for a total transaction of $155,312.50. Following the completion of the transaction, the executive vice president now owns 167,084 shares of the company’s stock, valued at approximately $2,965,741. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Several hedge funds and institutional investors have recently bought and sold shares of RTRX. California State Teachers Retirement System increased its position in Retrophin by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 64,781 shares of the biopharmaceutical company’s stock worth $1,250,000 after buying an additional 1,129 shares during the period. Cornerstone Capital Management Holdings LLC. increased its position in Retrophin by 1,449.5% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 91,421 shares of the biopharmaceutical company’s stock worth $1,763,000 after buying an additional 85,521 shares during the period. Finally, Turner Investments L.P. increased its position in Retrophin by 61.6% in the fourth quarter. Turner Investments L.P. now owns 384,760 shares of the biopharmaceutical company’s stock worth $7,422,000 after buying an additional 146,720 shares during the period.

Retrophin, Inc is a biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.